Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
— Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA...
DNA
Umoja Biopharma Announces Appointment of Britton Russell as Chief Financial Officer
Britton Russell Britton Russell, Chief Financial Officer, Umoja Biopharma SEATTLE,, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., (Umoja),...
Ocugen Clinical Showcase Webcast Now Available
MALVERN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
GTG to launch U.S. Customer Digital Media Sales Campaign
MELBOURNE, Australia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”, “GTG”), is pleased to announce the...
Prime Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a...
Recludix Pharma to Participate in Two Investor Conferences in March
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging...
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE)...
HDAI to Present at ViVE 2024 on How Clinicians Can Put AI to Work
BOSTON, Feb. 26, 2024 /PRNewswire/ -- Health Data Analytics Institute (HDAI) – a company pioneering the integration of artificial intelligence into healthcare...
Global Paternity & Relationship Testing Services Market Forecasts 2023-2027 with Executive and Consultant Guides – Changing Values and DTC are Creating New Opportunities
DUBLIN, Feb. 26, 2024 /PRNewswire/ -- The "Paternity & Relationship Testing Services. Global Market Forecasts for Applications and Technologies with...
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
- Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion -BOSTON, Feb. 26, 2024 (GLOBE NEWSWIRE) --...
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
Data expected to be shared during March corporate update With SAD cohorts complete, MAD cohorts to begin dosing in March...
MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial
MindBio demonstrates safe, effective take home use of MB22001 in Depressed patients over an 8-week, world first take-home trialRapid, robust,...
Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
BERKELEY, Calif. and MAINZ, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a...
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxisIRVINE, Calif., Feb. 22, 2024 (GLOBE...
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
Data Show Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccine Modality LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) --...
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing...
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of...
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
On track to dose the first patient in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin...
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI),...
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
Partnership Brings Pioneering Approach to Incorporating Advanced Colorectal Cancer Detection Into Country’s Healthcare SystemBERKELEY, Calif. and MAINZ, Germany, Feb. 21,...